Article Text

Download PDFPDF
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study
  1. R A Stockley1,
  2. N Chopra2,
  3. L Rice2,
  4. on behalf of the SMS40026 Investigator Group
  1. 1Department of Medicine, Queen Elizabeth Hospital, Birmingham B15 2HT, UK
  2. 2Department of Respiratory Medicine, GSK R&D, Greenford, Middlesex UB6 0HE, UK
  1. Correspondence to:
    Professor Robert Stockley
    Department of Medicine, Queen Elizabeth Hospital, Birmingham B15 2HT, UK; r.a.stockley{at}bham.ac.uk

Abstract

Background: This study investigated the addition of salmeterol to existing treatment for exacerbations in patients with poorly reversible chronic obstructive pulmonary disease (COPD).

Methods: 634 patients aged >40 years with a history of COPD exacerbations (including at least two in the previous year) and poor reversibility of airflow obstruction (⩽10% predicted forced expiratory volume in 1 second) received either salmeterol 50 μg or placebo twice daily from a Diskus inhaler for 12 months. The primary outcome was the number of moderate and severe exacerbations.

Results: The median rate of moderate or severe exacerbations in the intent-to-treat (ITT) population was lower in the salmeterol group (0.00, range 0.0–9.8, n = 316) than in the placebo group (0.93, range 0.0–13.0, n = 318), but the difference was not statistically significant (p = 0.27). The median rate of exacerbations in the per protocol population (>90% compliance) was also found to be lower in the salmeterol group (0.00, range 0.0–5.0, n = 206) than in the placebo group (0.93, range 0.0–5.6, n = 195) and did reach statistical significance (p = 0.007). For secondary end points, patients receiving salmeterol had significant improvement in lung hyperinflation measured by inspiratory capacity which was evident at 4 weeks and maintained over 12 months (p = 0.035), and a significant improvement in health status measured by the St George’s Respiratory Questionnaire at 12 months (p = 0.002).

Conclusion: Salmeterol has a positive effect on symptoms and health status of patients with COPD when added to usual treatment. Exacerbations are only reduced in patients who comply with treatment.

  • COPD, chronic obstructive pulmonary disease
  • FEV1, forced expiratory volume in 1 second
  • FVC, forced vital capacity
  • IC, inspiratory capacity
  • ICS, inhaled corticosteroid
  • ITT, intent-to-treat
  • LABA, long acting β agonist
  • MMEF, maximum mid-expiratory flow
  • PPP, per protocol population
  • SGRQ, St George’s Respiratory Questionnaire
  • SVC, slow vital capacity
  • chronic obstructive pulmonary disease
  • exacerbations
  • inspiratory capacity
  • salmeterol

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • This manuscript was prepared on behalf of an international study group from 19 countries: G Kaik, N Vetter (Austria); D Popov, D Osmanliev, K Kissiova, P Mandulova, J J Ivanov (Bulgaria); J B Martinot, D Rozen, R Louis, R Pauwels, I J M Stappaerts (Belgium); N Tudoric, F Pavicic, Z Beg Zec, S Skrinjaric Cincar, I Gudelj (Croatia); J Musil, J Krepelka, A Matulova, R Kasak (Czech Republic); J Korsgaard, F F Madsen, H Harving, J I Jensen, P Garsdal (Denmark); S Lane, T McDonnell (Ireland); T Kipper, L Raudla (Estonia); P Hyvernat, M Legendre, P Zuck, S Beaujot, J P Moreau, E Fournier, P Godard, T Similowski, F Ruff, G Pecastaing, N Roche, B Lebrozec, J Y Jasnot (France); H ten Hoff, A Benedix, J Eller, E Liefring, U Westerhausen, W Zachgo, J Bargon, W Westphal (Germany); H Berendsen, H Sinninghe Damste (Holland); I Herjavecz, K Radich, E Juhász, Z Márk, M Jedlinszki, I Áchim (Hungary); V Silins, J Krams (Latvia); W Droszcz, A Szczeklik, M Slominski, J Kruszewski (Poland); J Sanchís, M Rosales Jaldo, S Bardagi, C Esteban, J Serra, JM Rodriguez (Spain); E Rozborilova, P Kristufek, J Mazal, J Simovicova (Slovak Republic); J Sorli, R Kopriva, S Kajba (Slovenia); Y Yashyna, Y Feschenko (Ukraine); G Basran, P M A Calverley, M Wilkins, B Higgins (UK).

  • Funding for the study was provided by Glaxo Wellcome Research and Development (protocol SMS40026).

  • Competing interests: none declared.